Form 4: Disc Medicine CFO Sells Shares Under Pre-Arranged Trading Plan

Disc Medicine's Chief Financial Officer, Jean M. Franchi, sold 2,000 shares of common stock for approximately $52.26 per share on June 16, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (IRON), reported the sale of 2,000 shares of the company's common stock.
• The transaction took place on June 16, 2025.
• The shares were sold at a weighted average price of $52.2594 per share, with individual transaction prices ranging from $51.79 to $52.61.
• Following this sale, Ms. Franchi beneficially owns 67,530 shares of Disc Medicine common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was established on March 10, 2025.

Sentiment

Score: 5

Explanation: The document reports a routine insider stock sale conducted under a pre-planned Rule 10b5-1 plan, which is generally considered neutral as it mitigates concerns about opportunistic selling.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction designed to avoid accusations of insider trading and demonstrating adherence to corporate governance best practices.

Negatives

• The Chief Financial Officer sold 2,000 shares of company stock, which reduces their direct ownership in the company.

Risks

• Potential for negative market perception related to insider selling, although this is largely mitigated by the disclosure that the transaction was conducted under a pre-arranged Rule 10b5-1 plan.

Future Outlook

N/A

Management Comments

• "The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2025."
• "The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."

Industry Context

N/A

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the pre-planned nature under a Rule 10b5-1 plan helps to alleviate concerns about the underlying health or prospects of the company.

Key Dates

Keywords

Disc Medicine, IRON, insider trading, Form 4, stock sale, CFO, Jean M. Franchi, Rule 10b5-1